Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott latest victim of FDA’s missed PDUFA dates

Executive Summary

Abbott Laboratories joins the ranks of pharma companies whose PDUFA action dates for NDAs have passed, as FDA told the company this week it needs more time to review its cholesterol drug TriLipix (ABT-335), a next-generation fenofibrate. The agency did not request additional data or extend the drug's PDUFA date. Abbott joins a long list of drug companies affected by the resource-strapped agency (1"The Pink Sheet," Sept. 29, 2008, p. 21). Abbott still expects a fourth quarter approval. It was a rough week for Abbott, as the company also received a complete response letter Oct. 20 from FDA for its NDA for a controlled-release form of hydrocodone with acetaminophen

You may also be interested in...



FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins

FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins

Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris

Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.

Inside US FDA’s Return To In-Person Meetings

In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel